By Counterforce Health Team in Myozyme (alglucosidase alfa) —

UnitedHealthcare's Coverage Criteria for Myozyme (Alglucosidase Alfa) in New York: What Counts as "Medically Necessary"?

Answer Box: Getting Myozyme Covered by UnitedHealthcare in New York

To get Myozyme (alglucosidase alfa) approved by UnitedHealthcare in New York, you need: confirmed Pompe disease diagnosis (genetic testing + enzyme deficiency), specialist evaluation by a neurologist or metabolic physician, and prior authorization with comprehensive clinical documentation. If denied, New York's external appeal process through the Department of Financial Services provides a binding second opinion within 30 days. Start today: Have your specialist submit a complete prior authorization request through the UnitedHealthcare provider portal with genetic testing results, enzyme activity levels, and a detailed medical necessity letter.

Table of Contents

  1. Policy Overview: How UnitedHealthcare Handles Myozyme
  2. Indication Requirements: FDA Status and Clinical Criteria
  3. Step Therapy and Medical Exceptions
  4. Quantity and Frequency Limits
  5. Required Diagnostics and Documentation
  6. Site of Care and Specialty Pharmacy Requirements
  7. Evidence to Support Medical Necessity
  8. Sample Medical Necessity Framework
  9. Common Denial Reasons and Solutions
  10. New York Appeals Process
  11. Quick Reference: Coverage Checklist

Policy Overview: How UnitedHealthcare Handles Myozyme

UnitedHealthcare requires prior authorization for Myozyme across all plan types—commercial HMO/PPO, Medicare Advantage, and Medicaid managed care plans in New York. The drug is typically covered under the medical benefit rather than pharmacy benefit due to its IV infusion requirement.

Plan Type Variations:

  • Commercial plans: Standard prior authorization with 72-hour decision timeline
  • Medicare Advantage: May require specialist referrals; temporary waiver through April 2026 for some plans
  • Medicaid managed care: Additional state-level requirements may apply

Coverage decisions are based on UnitedHealthcare's enzyme replacement therapy policy, which outlines specific clinical criteria that must be met for approval.

Indication Requirements: FDA Status and Clinical Criteria

Myozyme is FDA-approved for treating Pompe disease (glycogen storage disease type II) in patients with confirmed enzyme deficiency. UnitedHealthcare's medical necessity determination requires:

Primary Diagnosis Requirements:

  • Confirmed Pompe disease diagnosis through both genetic testing (GAA gene mutations) and enzyme activity testing
  • GAA enzyme activity <40% of normal mean for late-onset Pompe disease
  • GAA enzyme activity <1% of normal mean for infantile-onset Pompe disease
  • Clinical symptoms consistent with Pompe disease (muscle weakness, respiratory dysfunction, or cardiac involvement)

Documentation Standards:

  • Genetic testing results showing pathogenic GAA gene mutations
  • Enzyme activity assay from certified laboratory
  • Clinical notes from neurologist or metabolic disease specialist
  • Baseline functional assessments (pulmonary function tests, muscle strength testing)
Note: Enzyme testing alone is insufficient for coverage approval. Both genetic confirmation and enzyme deficiency must be documented.

Step Therapy and Medical Exceptions

UnitedHealthcare may apply step therapy requirements for Myozyme, though specific protocols vary by plan and clinical presentation.

Typical Step Therapy Sequence:

  1. Documentation that no alternative treatments are appropriate for Pompe disease
  2. Confirmation that patient has not responded to supportive care measures
  3. Evidence that enzyme replacement therapy is the standard of care

Medical Exception Pathways:

  • Contraindication to alternatives: Document why other treatments are inappropriate
  • Previous trial and failure: Evidence of inadequate response to supportive therapies
  • Clinical urgency: Rapid disease progression requiring immediate intervention

To request a step therapy exception, submit clinical documentation showing why Myozyme is the most appropriate first-line treatment for the patient's specific presentation.

Quantity and Frequency Limits

Myozyme dosing follows strict FDA guidelines based on patient weight and clinical response.

Standard Dosing Parameters:

  • Dose: 20 mg/kg body weight every 2 weeks
  • Infusion duration: Approximately 4 hours per session
  • Quantity calculation: Based on patient's current weight (dose may require adjustment as weight changes)

UnitedHealthcare Quantity Limits:

  • Quantities must align with FDA-approved dosing
  • Dose increases require additional clinical justification
  • Frequency cannot exceed every 2 weeks without exceptional circumstances

Renewal Requirements:

  • Annual reauthorization required
  • Updated clinical assessments showing treatment benefit
  • Functional status evaluations comparing baseline to current status

Required Diagnostics and Documentation

UnitedHealthcare requires comprehensive diagnostic evidence before approving Myozyme coverage.

Essential Laboratory Tests:

  • Genetic testing: GAA gene sequencing showing pathogenic mutations
  • Enzyme activity: GAA enzyme level in lymphocytes, skin fibroblasts, or muscle tissue
  • Timing: Tests must be performed within 6 months of initial authorization request

Clinical Assessments:

  • Pulmonary function tests (FVC, FEV1, respiratory muscle strength)
  • Cardiac evaluation (ECHO, EKG if cardiac involvement suspected)
  • Muscle strength testing (manual muscle testing or quantitative assessment)
  • Functional capacity measures (6-minute walk test, timed function tests)

Specialist Evaluation: UnitedHealthcare requires evaluation by a neurologist or metabolic disease specialist who can provide:

  • Detailed clinical assessment
  • Treatment plan and monitoring strategy
  • Medical necessity letter supporting ERT initiation

Site of Care and Specialty Pharmacy Requirements

Myozyme administration must occur at UnitedHealthcare-approved infusion sites with appropriate safety protocols.

Approved Administration Sites:

  • Hospital outpatient infusion centers
  • Physician office-based infusion suites
  • Ambulatory surgical centers with infusion capabilities
  • Home infusion (with appropriate nursing support and emergency protocols)

Specialty Pharmacy Considerations: While Myozyme is not explicitly listed in UnitedHealthcare's mandatory specialty pharmacy sourcing requirements, providers should verify current sourcing requirements for each patient's specific plan.

Safety Requirements:

  • Facilities must have emergency protocols for anaphylaxis
  • Trained nursing staff experienced with ERT administration
  • Access to emergency medications and equipment

Evidence to Support Medical Necessity

Strong clinical documentation is essential for Myozyme approval. Reference established guidelines and peer-reviewed literature to support your request.

Key Supporting Evidence:

  • FDA prescribing information: Official dosing and indication guidance
  • Pompe disease treatment guidelines: International consensus recommendations
  • Clinical trial data: Efficacy studies supporting ERT in Pompe disease
  • Functional assessments: Objective measures showing disease impact

Clinical Rationale Framework:

  1. Diagnosis confirmation: Clear documentation of Pompe disease with appropriate testing
  2. Disease severity: Functional impairment requiring intervention
  3. Treatment appropriateness: ERT as standard of care for confirmed Pompe disease
  4. Monitoring plan: Strategy for assessing treatment response

Sample Medical Necessity Framework

A comprehensive medical necessity letter should include these key elements:

Patient Summary: "[Patient name] is a [age]-year-old with genetically confirmed Pompe disease (GAA gene mutations: [specify]) and enzyme deficiency ([specific GAA activity level]). Clinical presentation includes [muscle weakness/respiratory dysfunction/cardiac involvement] with functional impairment documented by [specific assessments]."

Treatment Rationale: "Enzyme replacement therapy with Myozyme represents the standard of care for Pompe disease, as supported by FDA approval and international treatment guidelines. The patient's confirmed enzyme deficiency and progressive symptoms warrant immediate initiation of ERT to prevent further functional decline."

Monitoring Plan: "Treatment response will be monitored through [quarterly/semi-annual] assessments including pulmonary function testing, muscle strength evaluation, and functional capacity measures. Dosing will be adjusted based on weight and clinical response."

Common Denial Reasons and Solutions

Understanding typical denial patterns helps prevent delays and strengthens appeal cases.

Denial Reason Solution Strategy Required Documentation
Insufficient diagnostic evidence Submit complete genetic and enzyme testing GAA gene sequencing + enzyme activity assay
Lack of specialist evaluation Obtain neurologist/metabolic specialist consultation Specialist consultation notes and recommendations
Missing prior authorization Submit complete PA request through provider portal All required forms and clinical documentation
Dosing outside guidelines Justify dose based on FDA labeling and patient weight Weight-based dosing calculation and clinical rationale
Site of care concerns Document appropriate infusion facility capabilities Facility accreditation and safety protocol documentation

New York Appeals Process

New York provides robust appeal rights for patients denied coverage for medically necessary treatments like Myozyme.

Internal Appeals (UnitedHealthcare):

  • Timeline: Must be filed within 180 days of denial
  • Decision timeframe: Standard appeals decided within 30 days; expedited within 72 hours
  • Required documents: Complete medical records, specialist letters, clinical justification

External Appeals (New York DFS): If UnitedHealthcare upholds the denial, you can file an external appeal with the New York State Department of Financial Services.

  • Timeline: Must be filed within 4 months of final internal denial
  • Cost: $25 fee (waived for financial hardship or Medicaid)
  • Decision: Binding determination within 30 days (72 hours for expedited)
  • Success rate: Many rare disease appeals are overturned with proper documentation

Appeal Documentation Checklist:

  • Copy of original denial letter
  • All medical records supporting diagnosis
  • Specialist evaluation and treatment recommendations
  • Relevant medical literature and guidelines
  • Patient impact statement (functional limitations)
Tip: Search the DFS external appeals database for similar Myozyme cases to strengthen your appeal with precedent decisions.

For personalized guidance navigating insurance denials and appeals, Counterforce Health helps patients and clinicians turn denials into targeted, evidence-backed appeals by analyzing denial letters, plan policies, and clinical notes to craft point-by-point rebuttals aligned with payer requirements.

Quick Reference: Coverage Checklist

Before Submitting Prior Authorization:

  • Confirmed Pompe disease diagnosis (genetic + enzyme testing)
  • Neurologist or metabolic specialist evaluation
  • Baseline functional assessments completed
  • Weight-based dosing calculation
  • Approved infusion site identified
  • Complete medical necessity letter prepared

Required Documentation:

  • Prior authorization form (submitted via UHC provider portal)
  • GAA gene sequencing results
  • Enzyme activity assay results
  • Specialist consultation notes
  • Pulmonary function tests
  • Muscle strength assessments
  • Treatment plan and monitoring strategy

Timeline Expectations:

  • Prior authorization decision: 72 hours (standard) / 24 hours (expedited)
  • Internal appeal: 30 days (standard) / 72 hours (expedited)
  • External appeal (NY DFS): 30 days (standard) / 72 hours (expedited)

Emergency Contacts:

  • UnitedHealthcare Provider Services: Check member portal for current number
  • New York DFS Consumer Hotline: 800-400-8882
  • Community Health Advocates: 888-614-5400

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual plan benefits and clinical circumstances. Always consult with your healthcare provider and insurance plan for specific coverage determinations.

For additional help with insurance appeals and coverage issues in New York, contact Community Health Advocates at 888-614-5400 or visit the New York State Department of Financial Services consumer assistance page.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.